Drug Trial Radar · NCT05229497
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
Last checked: Nov 19, 2026Latest source record: Mar 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
154
Planned (sponsor's estimate)
Start
May 4, 2022
Primary completion
Dec 31, 2026
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- Feb 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK112 (anti-PD-1 and VEGF bispecific antibody) combined with AK117#AntiCD47 Antibody# in advanced malignant tumors
Conditions
- Advanced Malignant Tumors
Interventions
AK112Drug
IV infusion,Specified dose on specified days
AK117Drug
IV infusion,Specified dose on specified days
CarboplatinDrug
IV infusion,Specified dose on specified days
CisplatinDrug
IV infusion,Specified dose on specified days
5-FluorouracilDrug
IV infusion,Specified dose on specified days
GemcitabineDrug
IV infusion,Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients with Adverse Events (AEs)Time frame: Up to approximately 2 years
- Number of patients experiencing dose-limiting toxicities (DLTs)Time frame: During the first 3 weeks
- Objective Response Rate (ORR)Time frame: Up to approximately 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.